Now showing items 1-5 of 5

    • Díaz Jara, Jorge; Woudt, Lisanne; Suazo Rojas, Lionel Andrés; Garrido Inostroza, Cristian Alejandro; Caviedes Fernández, Pablo; Cárdenas, Ana María; Bevilacqua, Jorge (2016)
      Introduction: MRI characterization of dysferlinopathy has been mostly limited to the lower limbs. We aimed to broaden the MRI description of dysferlinopathy and to correlate it with objective measures of motor dysfunction. ...
    • Báez Matus, Ximena; Figueroa Cares, Cindel; González Jamett, Arlek M.; Almarza Salazar, Hugo; Arriagada, Christian; Maldifassi, María Constanza; Guerra, María José; Mouly, Vincent; Bigot, Anne; Caviedes Fernández, Pablo; Cárdenas, Ana M. (MDPI, 2020)
      Dysferlin is a transmembrane C-2 domain-containing protein involved in vesicle trafficking and membrane remodeling in skeletal muscle cells. However, the mechanism by which dysferlin regulates these cellular processes ...
    • García Campos, Paz; Báez Matus, Ximena; Jara Gutiérrez, Carlos; Paz Araos, Marilyn; Astorga, César; Cea, Luis A.; Rodríguez, Viviana; Bevilacqua, Jorge A.; Caviedes, Pablo; Cárdenas, Ana M. (MDPI, 2020)
      Dysferlinopathy is an autosomal recessive muscular dystrophy resulting from mutations in the dysferlin gene. Absence of dysferlin in the sarcolemma and progressive muscle wasting are hallmarks of this disease. Signs of ...
    • Cea Pisani, Luis Andrés; Bevilacqua, Jorge; Arriagada Abarzúa, Christian; Cárdenas, Ana María; Bigot, Anne; Mouly, Vincent; Sáez, Juan C.; Caviedes Fernández, Pablo (2016)
      Background: Mutations in the gene encoding for dysferlin cause recessive autosomal muscular dystrophies called dysferlinopathies. These mutations induce several alterations in skeletal muscles, including, inflammation, ...
    • Woudt, Lisanne; Di Capua, Gabriella A.; Krahn, Martin; Castiglioni, Claudia; Hughes García, Ricardo; Campero Soffia, Mario; Trangulao, Alejandra; González Hormazabal, Patricio; Godoy Herrera, Raúl; Levy, Nicolas; Urtizberea, Jon Andoni; Jara, Lilian; Bevilacqua, Jorge (WILEY-BLACKWELL, 2016)
      Introduction: Understanding the natural history of dysferlinopathy is essential to design and quantify novel therapeutic protocols. Our aim in this study was to assess, clinically and functionally, a cohort of patients ...